Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 15;210(8):1248-59.
doi: 10.1093/infdis/jiu254. Epub 2014 May 1.

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment

Allan R Tenorio  1 , Yu Zheng  2 , Ronald J Bosch  2 , Supriya Krishnan  2 , Benigno Rodriguez  3 , Peter W Hunt  4 , Jill Plants  5 , Arjun Seth  3 , Cara C Wilson  6 , Steven G Deeks  4 , Michael M Lederman  3 , Alan L Landay  5
Affiliations

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment

Allan R Tenorio et al. J Infect Dis. .

Abstract

Background: Defining the association of non-AIDS-defining events with inflammation and immune activation among human immunodeficiency virus (HIV)-infected persons with antiretroviral therapy (ART)-associated virological suppression is critical to identifying interventions to decrease the occurrence of these events.

Methods: We conducted a case-control study of HIV-infected subjects who had achieved virological suppression within 1 year after ART initiation. Cases were patients who experienced non-AIDS-defining events, defined as myocardial infarction, stroke, non-AIDS-defining cancer, non-AIDS-defining serious bacterial infection, or death. Controls were matched to cases on the basis of age, sex, pre-ART CD4(+) T-cell count, and ART regimen. Peripheral blood mononuclear cells and plasma specimens obtained at the visit before ART initiation (hereafter, baseline), the visit approximately 1 year after ART initiation (hereafter, year 1), and the visit immediately preceding the non-AIDS-defining event (hereafter, pre-event) were analyzed for activated CD4(+) and CD8(+) T cells, plasma interleukin 6 (IL-6) level, soluble tumor necrosis factor receptor I (sTNFR-I) level, sTNFR-II level, soluble CD14 level, kynurenine-to-tryptophan (KT) ratio, and D-dimer level. Conditional logistic regression analysis was used to study the association between biomarkers and outcomes, with adjustment for potential confounders.

Results: Higher IL-6 level, sTNFR-I level, sTNFR-II level, KT ratio, and D-dimer level at year 1 were associated with the occurrence of a non-AIDS-defining event. Significant associations were also seen between non-AIDS-defining events and values of these biomarkers in specimens obtained at baseline and the pre-event time points. Effects remained significant after control for confounders. T-cell activation was not significantly related to outcomes.

Conclusions: Interventional trials to decrease the incidence of non-AIDS-defining events among HIV-infected persons with virological suppression should consider targeting the pathways represented by these soluble markers. Clinical Trials Registration. NCT00001137.

Keywords: ART; HIV; Non-AIDS morbidity; immune activation; inflammation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Timing of non–AIDS-defining events in relation to time in years after antiretroviral therapy (ART) initiation. Fatal cases are indicated by solid black circles. Abbreviations: MI, myocardial infarction; SBI, serious bacterial infection.
Figure 2.
Figure 2.
Median levels of soluble markers of inflammation and coagulation between cases (open circle) and controls (x) in specimens obtained at the visit before antiretroviral therapy (ART) initiation (baseline), the visit approximately 1 year after ART initiation (year 1), and the visit immediately preceding the non–AIDS-defining event (pre-event). Abbreviations: IL-6, interleukin 6; IP-10, interferon γ–inducible protein 10; sTNFR, soluble tumor necrosis factor receptor.
Figure 3.
Figure 3.
Biomarker levels in specimens obtained at the visit before antiretroviral therapy initiation (baseline) and odds ratios (ORs) of having a non–AIDS-defining event. Adjusted analyses controlled for log10 baseline human immunodeficiency virus RNA load. *P = .01 to <.05; **P < .01. Abbreviations: IL-6, interleukin 6; IP-10, interferon γ–inducible protein 10; IQR, interquartile range; KT, kynurenine to tryptophan; MI, myocardial infarction; sTNFR, soluble tumor necrosis factor receptor.
Figure 4.
Figure 4.
Biomarker levels in specimens obtained at the visit approximately 1 year after ART initiation (year 1) and odds ratios (ORs) of having a non–AIDS-defining event. Adjusted analyses controlled for concurrent CD4+ T-cell count. *P = .01 to <.05; **P < .01. Abbreviations: IL-6, interleukin 6; IP-10, interferon γ–inducible protein 10; IQR, interquartile range; KT, kynurenine to tryptophan; MI, myocardial infarction; sTNFR, soluble tumor necrosis factor receptor.
Figure 5.
Figure 5.
Biomarker levels in specimens obtained at the visit immediately preceding the non–AIDS-defining event (pre-event) and odds ratios (ORs) of having a non–AIDS-defining event. Adjusted analyses controlled for concurrent CD4+ T-cell count. *P = .01 to <.05; **P < .01. Abbreviations: IL-6, interleukin 6; IP-10, interferon γ–inducible protein 10; IQR, interquartile range; KT, kynurenine to tryptophan; MI, myocardial infarction; sTNFR, soluble tumor necrosis factor receptor.
Figure 6.
Figure 6.
Median levels of T-cell markers of activation and senescence between cases (open circle) and controls (x) in specimens obtained at the visit before antiretroviral therapy (ART) initiation (baseline), the visit approximately 1 year after ART initiation (year 1), and the visit immediately preceding the non–AIDS-defining event (pre-event).
See this image and copyright information in PMC

Comment in

References

    1. Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9. - PMC - PubMed
    1. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203–8. - PMC - PubMed
    1. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36. - PubMed
    1. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471–7. - PubMed
    1. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228–30. - PubMed

Publication types

Associated data